So Big Pharma’s argument about pricing goes like this: We spend a lot on R&D so we need to make a lot back when we find a winner. Now with Pharmasset we can look at the balance sheet immediately prior to Gilead’s purchase. At the time the sunk capital cost (accumulated deficit) was $324 million. […]
